MD Anderson doubles up on cancer 'Moon Shots'

MD Anderson, which has attracted a who's who in immuno-oncology as partners for its Moon Shots R&D program, is adding 6 new cancers to its list of targets. The research institution is doubling down on its moon shots, adding B-cell lymphomas, glioblastoma, HPV, multiple myeloma, colorectal and pancreatic cancers to the list. "As the Moon Shots Program matures, we're transitioning from the foundational phase to the results phase, and some moon shots already are making practice-changing advances in the clinic and in cancer prevention and control," says MD Anderson's Ronald DePinho. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.